Fig. 3
From: Bone marrow stem cells to destroy circulating HIV: a hypothetical therapeutic strategy
Combination therapy to transfuse riBFU-E and riRBC into HIV-positive patient. riBFU-E and riRBCs will be transfused into peripheral blood of HIV patients as combination therapeutic strategy. Once inside patients’ body, riRBCs will be immediately functional to counter circulating HIV particles. On the other hand, riBFU-E from the peripheral blood will find its way to the bone marrow by stem cell homing and will normally differentiate into riRBC that will further amplify the efficiency of the therapy. riRBCs receptor integrated red blood corpuscles, riBFU-E receptor integrated burst forming unit-erythroid